Literature DB >> 2211651

Regulation of the expression of Gal alpha 1-3Gal beta 1-4GlcNAc glycosphingolipids in kidney.

S P Hendricks1, P He, C L Stults, B A Macher.   

Abstract

Previous studies (Galili, U., Clark, M. R., Shohet, S. B., Buehler, J., and Macher, B. A. (1987) Proc. Natl. Acad. Sci. U. S. A. 84, 1369-1373; Galili, U., Shohet, S. B., Korbrin, E., Stults, C. L. M., and Macher, B. A. (1988) J. Biol. Chem. 263, 17755-17762) have established that there is a unique evolutionary distribution of glycoconjugates carrying the Gal alpha 1-3Gal beta 1-4GlcNAc epitope. These glycoconjugates are expressed by cells from New World monkeys and non-primate mammals, but not by cells from humans, Old World monkeys, or apes. The lack of expression of this epitope in the latter species appears to result from the suppression of gene expression for the enzyme UDP-galactose:nLc4Cer alpha 1-3-galactosyltransferase (alpha 1-3GalT) (Joziasse, D. H., Shaper, J. H., Van den Eijnden, D. H., Van Tunen, A. J., and Shaper, N. L. (1989) J. Biol. Chem. 264, 14290-14297). Although many non-primate species are known to express this carbohydrate epitope, the nature (i.e. glycoprotein or glycosphingolipid) of the glycoconjugate carrying this epitope is only known for a few tissues in a few animal species. Furthermore, it is not known whether all animal species express this epitope in the same tissues. We have investigated these questions by analyzing the glycosphingolipids in kidney from several non-primate animal species. Immunostained thin layer chromatograms of glycosphingolipids from sheep, pig, rabbit, cow, and rat kidney with the Gal alpha 1-3Gal beta 1-4GlcNAc glycosphingolipid-specific monoclonal antibody, Gal-13, demonstrated that kidney from all of these species except rat contained Gal alpha 1-3Gal beta 1-4GlcNAc neutral glycosphingolipids. A lack of expression of Gal alpha 1-3Gal beta 1-4GlcNAc glycosphingolipids in rat may be due to the lack of expression of the enzyme (alpha 1-3GalT) which catalyzes the formation of the Gal alpha 1-3Gal nonreducing terminal sequence of these compounds or to the lack of expression of glycosyltransferases which are necessary for the synthesis of the neolacto core structure of these compounds. These possibilities were evaluated in two ways. First, the three enzymes (UDP-N-acetylglucosamine:LacCer beta 1-3-N-acetyl-glucosaminyltransferase, UDP-galactose:Lc3Cer beta 1-4-galactosyltransferase, and alpha 1-3GalT) involved in the synthesis of the Gal alpha 1-3Gal beta 1-4GlcNAc glycosphingolipids were assayed using an enzyme-linked immunosorbent assay-based assay system and carbohydrate sequence-specific monoclonal antibodies. Second, TLC immunostaining was done to determine if the glycosphingolipid precursors (i.e. Lc3Cer and nLc4Cer) are expressed in rat kidney. Interestingly, rat kidney had a relatively high level of alpha 1-3GalT activity compared with the other animals tested.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2211651

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  12 in total

1.  Expression of a unique globo-series glycolipid in cultured rat dorsal root ganglion neurons: relationship with neuronal development.

Authors:  S Pal; J W Bigbee; M Saito; T Ariga; R K Yu
Journal:  Neurochem Res       Date:  1996-04       Impact factor: 3.996

2.  Two novel isoneolacto-undecaglycosylceramides carrying Galalpha1-->3Lewis(x) on the 6-linked antenna and N-acetylneuraminic acidalpha2-->3 or Galactose alpha1-->3 on the 3-linked antenna, expressed in porcine kidney.

Authors:  D Bouhours; J Liaigre; J Lemoine; F Mayer-Posner; J F Bouhours
Journal:  Glycoconj J       Date:  1998-10       Impact factor: 2.916

3.  The expression and distribution of α-Gal gene in various species ocular surface tissue.

Authors:  Yi Shao; Yao Yu; Chong-Gang Pei; Yangluowa Qu; Gui-Ping Gao; Ji-Lin Yang; Qiong Zhou; Lu Yang; Qiu-Ping Liu
Journal:  Int J Ophthalmol       Date:  2012-10-18       Impact factor: 1.779

4.  On the cause and consequences of IgE to galactose-α-1,3-galactose: A report from the National Institute of Allergy and Infectious Diseases Workshop on Understanding IgE-Mediated Mammalian Meat Allergy.

Authors:  Thomas A E Platts-Mills; Scott P Commins; Tilo Biedermann; Marianne van Hage; Michael Levin; Lisa A Beck; Maria Diuk-Wasser; Uta Jappe; Danijela Apostolovic; Michael Minnicozzi; Marshall Plaut; Jeffrey M Wilson
Journal:  J Allergy Clin Immunol       Date:  2020-02-10       Impact factor: 10.793

Review 5.  Evolution and pathophysiology of the human natural anti-alpha-galactosyl IgG (anti-Gal) antibody.

Authors:  U Galili
Journal:  Springer Semin Immunopathol       Date:  1993

6.  Enzyme-linked immunosorbent assays for the measurement of blood group A and B glycosyltransferase activities.

Authors:  L M Keshvara; E M Newton; A H Good; O Hindsgaul; M M Palcic
Journal:  Glycoconj J       Date:  1992-02       Impact factor: 2.916

7.  Characterization of porcine kidney neutral glycosphingolipids: identification of a carbohydrate antigen recognized by human natural antibodies.

Authors:  K Jalali-Araghi; B A Macher
Journal:  Glycoconj J       Date:  1994-06       Impact factor: 2.916

8.  A unique combination of glycoside hydrolases in Streptococcus suis specifically and sequentially acts on host-derived αGal-epitope glycans.

Authors:  Ping Chen; Ran Liu; Mengmeng Huang; Jinlu Zhu; Dong Wei; Francis J Castellino; Guanghui Dang; Fang Xie; Gang Li; Ziyin Cui; Siguo Liu; Yueling Zhang
Journal:  J Biol Chem       Date:  2020-06-09       Impact factor: 5.157

Review 9.  The Galalpha1,3Galbeta1,4GlcNAc-R (alpha-Gal) epitope: a carbohydrate of unique evolution and clinical relevance.

Authors:  Bruce A Macher; Uri Galili
Journal:  Biochim Biophys Acta       Date:  2007-11-22

Review 10.  Environmental and Molecular Drivers of the α-Gal Syndrome.

Authors:  Alejandro Cabezas-Cruz; Adnan Hodžić; Patricia Román-Carrasco; Lourdes Mateos-Hernández; Georg Gerhard Duscher; Deepak Kumar Sinha; Wolfgang Hemmer; Ines Swoboda; Agustín Estrada-Peña; José de la Fuente
Journal:  Front Immunol       Date:  2019-05-31       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.